Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trolox methyl ether is a lipophilic small molecule and a synthetic derivative of Trolox, which is a water-soluble analog of Vitamin E (alpha-tocopherol). It functions as a potent antioxidant and radical scavenger, specifically designed to neutralize reactive oxygen species (ROS) and mitigate oxidative stress-induced cellular damage. The modification of the parent Trolox molecule to a methyl ether (or ester) form significantly increases its lipophilicity, thereby enhancing its ability to cross biological membranes and the blood-brain barrier. Trolox methyl ether has been primarily investigated in preclinical research for its neuroprotective potential in neurodegenerative conditions, most notably Parkinson's disease. In toxin-induced animal models such as the MPTP mouse model, it has been evaluated for its capacity to protect dopaminergic neurons and reduce dopamine turnover, with research suggesting that its efficacy may be dose-dependent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trolox methyl ether.